Table 4.
Number of subjects with positive serology to the nine types assayed by the Total IgG and cLIA assays. N=95
| Assay Type |
HPV Type | Assay Cutoff** |
Number Positive at enrollment, N (%) |
Number Positive at second collection N (%) |
Median titer at enrollment* |
Median titer at second collection* |
Rate of sero- conversion*** among all subjects N (%) |
|---|---|---|---|---|---|---|---|
| IgG | 6 | >15 | 22 (23.2) | 48 (50.5) | 31.0 | 52.5 | 29 (30.5) |
| IgG | 11 | >15 | 4 (4.2) | 17 (17.9) | 32.6 | 48.2 | 15 (15.8) |
| IgG | 16 | >7 | 37 (38.9) | 57 (60) | 10.6 | 49.0 | 28 (29.5) |
| IgG | 18 | >10 | 29 (30.5) | 40 (42.1) | 15.5 | 22.7 | 24 (25.3) |
| IgG | 31 | >6 | 9 (9.5) | 26 (27.4) | 10.3 | 16.5 | 20 (21.5) |
| IgG | 33 | >6 | 7 (7.4) | 14 (14.7) | 17.8 | 12.9 | 8 (8.4) |
| IgG | 45 | >17 | 5 (5.3) | 3 (3.2) | 18.5 | 45.7 | 3 (3.2) |
| IgG | 52 | >8 | 7 (7.4) | 23 (24.2) | 19.1 | 18.5 | 19 (20.0) |
| IgG | 58 | >6 | 9 (9.5) | 21 (22.1) | 18.7 | 18.5 | 16 (16.8) |
| cLIA | 6 | >20 | 23 (24.2) | 46 (48.4) | 44 | 123.5 | 27 (28.4) |
| cLIA | 11 | >16 | 2 (2.1) | 12 (12.6) | 81.5 | 37.0 | 9 (9.5) |
| cLIA | 16 | >20 | 6 (6.3) | 34 (35.8) | 315.0 | 184.5 | 27 (28.4) |
| cLIA | 18 | >24 | 6 (6.3) | 19 (20.0) | 52.0 | 77.0 | 14 (14.7) |
*
Median titer was calculated after excluding all negative serologies.
**
Any value greater than the number listed for that type-specific assay was considered positive.
***
Seroconversion was defined as any value below the cut-off for that type specific assay at enrollment and any value greater than the assay cut-off at the second collection.
IgG= Total IgG for each HPV type and cLIA= competitive luminex immunoassay for each HPV type listed.